Trial Profile
A Phase I-II Study of Triciribine Phosphate Monohydrate (PTX-200) Plus Cytarabine in Refractory or Relapsed Acute Leukemia
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 07 Feb 2023
Price :
$35
*
At a glance
- Drugs Cytarabine (Primary) ; PTX 200 (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors Prescient Therapeutics
- 08 Feb 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
- 08 Feb 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2021.
- 08 Jan 2020 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.